Inari Medical Inc. (NARI) News
Filter NARI News Items
NARI News Results
|Loading, please wait...|
NARI News Highlights
- For NARI, its 30 day story count is now at 3.
- Over the past 10 days, the trend for NARI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NARI are NOTE and TU.
Latest NARI News From Around the Web
Below are the latest news stories about INARI MEDICAL INC that investors may wish to consider to help them evaluate NARI as an investment opportunity.
Why Shares of Inari Medical Rose This Week
Shares of Inari Medical (NASDAQ: NARI) were up 16.9% for the week as of late Thursday afternoon, according to data provided by S&P Global Market Intelligence. Several executives of the healthcare company increased their ownership stake in the company this week, including former CEO and current board member William Hoffman, CFO Mitch Hill, CEO Drew Hykes, and Chief Medical Officer Thomas Tu.
Inari Medical, Inc. (NASDAQ:NARI) Q4 2022 Earnings Call Transcript
Inari Medical, Inc. (NASDAQ:NARI) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Good afternoon, and welcome to the Inari Medical Fourth Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now […]
FLAME Study Demonstrates 90% Survival Improvement in High-Risk Pulmonary Embolism with Inari Medical FlowTriever System
IRVINE, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced positive results from the FLAME study in high-risk/massive pulmonary embolism (“PE”). The data was presented during the Late-Breaking Clinical and Investigative Horizons session at the 2023 ACC (American College of Cardiology) conference on March 5th by national Prin
Inari Medical Full Year 2022 Earnings: EPS Beats Expectations
Inari Medical ( NASDAQ:NARI ) Full Year 2022 Results Key Financial Results Revenue: US$383.5m (up 38% from FY 2021...
Inari Medical (NARI) Q4 Earnings Beat, Revenues Rise Y/Y
Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all its growth drivers.
Inari Medical, Inc. (NARI) Reports Q4 Loss, Tops Revenue Estimates
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 35.29% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results
IRVINE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter Revenue and Recent Business Highlights Generated revenue of $107.8 million in the fourth quarter of 2022, up 12% sequentially and 30% over the same quarter last year,
12 Most Promising Medical Stocks According to Analysts
In this article, we will take a look at the 12 most promising medical stocks according to analysts. To see more such companies, go directly to 5 Most Promising Medical Stocks According to Analysts. Regardless of the short-term market situation, the healthcare industry has a huge growth potential. According to a report by McKinsey, healthcare […]
Analysts Estimate Inari Medical, Inc. (NARI) to Report a Decline in Earnings: What to Look Out for
Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.